T1	p 74 106	in anemic patients with cancer .
T2	p 222 275	patients with cancer-associated anemia . PATIENTS AND
T3	p 284 338	Eligible patients were randomly assigned at enrollment
T4	p 571 693	Three hundred sixty-five patients were enrolled . One hundred eighty-three patients were assigned to the 40K arm , and 182
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 372 415	epoetin alfa 40,000 U subcutaneously ( SC )
T9	i 437 467	standard weekly epoetin alfa (
T10	i 494 513	epoetin alfa ( 120K
T11	i 520 522	SC
T12	i 1544 1565	epoetin alfa 40,000 U
T13	i 1586 1587	U
T14	i 1751 1763	epoetin alfa
T15	o 757 802	proportion of patients requiring transfusions
T16	o 1170 1261	mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T17	o 1314 1344	global quality of life ( QOL )
T18	o 1426 1448	global QOL improvement
T19	o 1484 1487	QOL